Bionano Genomics (BNGO) Total Non-Current Liabilities (2017 - 2024)

Bionano Genomics' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $41.3 million for Q4 2024.

• In Q4 2024, Total Non-Current Liabilities fell 61.53% year-over-year to $41.3 million; the TTM figure through Dec 2024 stood at $41.3 million (down 61.53% YoY), while the FY2024 annual figure was $41.3 million, down 61.53% from the prior year.
• Total Non-Current Liabilities came in at $41.3 million for Q4 2024 at Bionano Genomics, up from $38.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $107.4 million in Q4 2023 to a low of $17.9 million in Q3 2021.
• A 5-year average of $41.3 million and a median of $41.3 million in 2024 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities soared 137.86% in 2023 and sank 61.53% in 2024, its largest moves.
• Bionano Genomics' Total Non-Current Liabilities stood at $25.4 million in 2020, then advanced by 21.87% to $30.9 million in 2021, then surged by 45.99% to $45.1 million in 2022, then soared by 137.86% to $107.4 million in 2023, then tumbled by 61.53% to $41.3 million in 2024.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $41.3 million, $38.5 million, and $43.3 million for Q4 2024, Q3 2024, and Q2 2024 respectively.

Peer Comparison